In re Cornerstone Therapeutics Inc. Stockholder Litigation

CourtCourt of Chancery of Delaware
DecidedSeptember 10, 2014
DocketCA 8922-VCG
StatusPublished

This text of In re Cornerstone Therapeutics Inc. Stockholder Litigation (In re Cornerstone Therapeutics Inc. Stockholder Litigation) is published on Counsel Stack Legal Research, covering Court of Chancery of Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In re Cornerstone Therapeutics Inc. Stockholder Litigation, (Del. Ct. App. 2014).

Opinion

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE

IN RE CORNERSTONE ) THERAPEUTICS INC. ) CONSOLIDATED STOCKHOLDER LITIGATION ) Civil Action No. 8922-VCG

MEMORANDUM OPINION

Date Submitted: June 5, 2014 Date Decided: September 10, 2014

Seth D. Rigrodsky, Brian D. Long, Gina M. Serra, and Jeremy J. Riley, of Rigrodsky & Long, P.A., Wilmington, Delaware; OF COUNSEL: Ira M. Press, J. Brandon Walker, and Melissa A. Fortunato, of Kirby McInerney LLP, New York, New York, Shane Rowley, of Levi & Korsinsky LLP, New York, New York, and Chet B. Waldman and Joshua H. Saltzman, of Wolf Popper LLP, New York, New York, Attorneys for the Plaintiffs.

Donald J. Wolfe, Jr., Kevin R. Shannon, and Christopher N. Kelly, of Potter Anderson & Corroon LLP, Wilmington, Delaware; OF COUNSEL: Anthony M. Candido, Robert C. Myers, and John P. Alexander, of Clifford Chance US LLP, New York, New York, Attorneys for Defendants Cornerstone Therapeutics Inc., Michael Enright, Christopher Codeanne, James H. Harper, Michael Heffernan, and Laura Shawver.

Kurt M. Heyman, Patricia L. Enerio, and Dawn Kurtz Crompton, of Proctor Heyman LLP, Wilmington, Delaware, Attorneys for Defendants Craig A. Collard and Robert M. Stephan.

GLASSCOCK, Vice Chancellor This case involves the acquisition of the minority interest in a corporation by

a controlling stockholder, in a manner alleged not to be entirely fair. Because the

controller is a fiduciary that stood on both sides of this transaction, the controller

will have to demonstrate on a developed record that the transaction was entirely

fair to the minority (or that mechanisms were in place approximating an arm’s-

length transaction, in which case its burden may be reduced). The Amended

Complaint also pleads breaches of fiduciary duty against directors of the company

appointed as members of a special committee formed to negotiate with the

controller and other disinterested directors who voted to recommend the

transaction, as well as a claim against the company for aiding and abetting

directors’ breaches of fiduciary duty. This Memorandum Opinion addresses those

defendants’ Motions to Dismiss.

I. FACTS

1. The Parties

Cornerstone Therapeutics Inc. (“Cornerstone,” or the “Company”) is a

publicly-traded Delaware pharmaceutical company, headquartered in Cary, North

Carolina.1 Cornerstone’s business “focuse[s] on commercializing products for the

hospital, niche respiratory, and related specialty products” industry by “acquiring

companies and . . . registration-stage products that fit within its focus areas,” and

1 The facts cited herein are taken from the Verified Amended Complaint unless otherwise indicated.

2 “marketing [those] products through its wholly-owned subsidiary, Aristos

Pharmaceuticals, Inc.”2 Craig A. Collard is the Company’s founder and, prior to

the February 3, 2014 merger at issue in this litigation (the “Merger”), was its CEO.

As of February 3, 2014, Cornerstone’s board of directors consisted of Collard,

Anton Giorgio Failla, Robert M. Stephan, Marco Vecchia, James A. Harper, Laura

Shawver, Christopher G. Codeanne, Michael D. Enright, and Michael Heffernan.

In May 2009, Chiesi Farmaceutici S.p.A. (“Chiesi”), a privately-held Italian

drug manufacturer, purchased 11,902,741 shares of Cornerstone common stock,

obtaining a controlling position in the Company, pursuant to a “series of

agreements with the Company and certain of its stockholders, including Collard,”3

in exchange for approximately $15.5 million in cash and a ten-year distribution

license for Chiesi’s “Curosoft” product, “a treatment for respiratory distress

syndrome in premature infants.”4 In connection with that transaction, Cornerstone

and Chiesi entered into a “Governance Agreement,” which granted Chiesi certain

majority stockholder rights and placed restrictions on Chiesi’s ability to make

purchases and transfers of Cornerstone stock. According to the Plaintiffs, “[a]s

part of the 2009 Chiesi Transaction, the Company agreed that Chiesi was permitted

to purchase additional shares from the Company, other stockholders, or on the

2 Am. Compl. ¶ 33. 3 Id. ¶ 49. 4 Id. ¶ 37.

3 market, such that Chiesi would be able to maintain its beneficial ownership of 51%

of Cornerstone’s outstanding common stock.”5

In December 2010, Chiesi purchased an additional 450,000 shares of

Cornerstone stock from entities controlled by Collard, after which Chiesi owned

55.51% of Cornerstone’s outstanding stock. In March 2012, pursuant to a Stock

Purchase Agreement, Chiesi purchased an additional 1,443,913 shares, increasing

its interest in Cornerstone to above 60%. In June 2012, Cornerstone and Chiesi

entered into a senior secured loan facility, pursuant to which Chiesi obtained a

right to convert certain debt to common stock, and became the beneficial owner of

65.4% of Cornerstone common stock.

2. The Special Committee

On February 18, 2013, Chiesi delivered to the Cornerstone board a letter (the

“Offer Letter”) “offering to acquire all of the outstanding shares of common stock

of Cornerstone not owned by Chiesi at a price range of $6.40 to $6.70 per share.”6

The Offer Letter explained that “[d]uring the last few months we have conducted

an extensive review of Cornerstone based on publicly available information, our

own deep experience in the pharmaceutical industry and consultations with our

outside advisors,” and that, “[a]t $6.40 to $6.70 per share, our proposal represents a

20% to 25% premium over [the] Friday, February 15, 2013 closing price of

5 Id. ¶ 38. 6 Id. ¶ 45.

4 $5.35.”7 The Offer Letter did not condition Chiesi’s offer on the approval of a

majority of the minority stockholders.

As noted above, in February 2013, Cornerstone’s board consisted of nine

directors. Of those nine directors, three had current or prior employment

relationships with Chiesi. Specifically, Failla served at that time as Head of

Business Development at Chiesi; Vecchia served “as Head of Legal and Corporate

Affairs at Chiesi and as a member of the board of directors of several Chiesi

subsidiaries;”8 and Stephan had “served as Vice President and Secretary from 1997

to 2012 and [had] served as a director from April 2009 to 2012 of Chiesi

Pharmaceuticals, Inc., USA, a subsidiary of Chiesi.”9

In response to Chiesi’s Offer Letter, the Cornerstone board formed a special

committee of five directors—Harper, Shawver, Codeanne, Enright, and Heffernan

(the “Special Committee”). Although the Defendants contend that the members of

the Special Committee were disinterested and independent, the Plaintiffs disagree.

Rather, the Plaintiffs allege that Harper and Shawver lacked independence in

evaluating Chiesi’s offer due to their involvement with Phenomix Corporation, Inc.

(“Phenomix”), a company that in 2009 signed a $191 million agreement with

Chiesi. At that time, Harper was a director, and Shawver was the CEO and a

7 Id. ¶ 50. 8 Id. ¶ 18. 9 Id. ¶ 17.

5 director, of Phenomix, but by 2013 Phenomix was defunct and existed only to

wind up its affairs. Although the Phenomix deal was consummated in 2009—

several years prior to Chiesi’s February 2013 Offer Letter—and Phenomix was

defunct by that time, the Plaintiffs contend that Harper and Shawver’s relationships

demonstrate that neither individual could have acted independently in evaluating

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Wardell v. Railroad Co.
103 U.S. 651 (Supreme Court, 1881)
Geddes v. Anaconda Copper Mining Co.
254 U.S. 590 (Supreme Court, 1921)
Stegemeier v. Magness
728 A.2d 557 (Supreme Court of Delaware, 1999)
Tanzer v. International General Industries, Inc.
379 A.2d 1121 (Supreme Court of Delaware, 1977)
Nixon v. Blackwell
626 A.2d 1366 (Supreme Court of Delaware, 1993)
Cinerama, Inc. v. Technicolor, Inc.
663 A.2d 1156 (Supreme Court of Delaware, 1995)
Malpiede v. Townson
780 A.2d 1075 (Supreme Court of Delaware, 2001)
David J. Greene & Co. v. Dunhill International, Inc.
249 A.2d 427 (Court of Chancery of Delaware, 1968)
Singer v. Magnavox Co.
380 A.2d 969 (Supreme Court of Delaware, 1977)
In Re General Motors Class H Shareholders Litigation
734 A.2d 611 (Court of Chancery of Delaware, 1999)
Citron v. E.I. Du Pont De Nemours & Co.
584 A.2d 490 (Court of Chancery of Delaware, 1990)
Roland International Corp. v. Najjar
407 A.2d 1032 (Supreme Court of Delaware, 1979)
Harman v. Masoneilan International, Inc.
442 A.2d 487 (Supreme Court of Delaware, 1982)
Kahn v. Lynch Communication Systems, Inc.
638 A.2d 1110 (Supreme Court of Delaware, 1994)
Weinberger v. UOP, Inc.
457 A.2d 701 (Supreme Court of Delaware, 1983)
Weinberger v. UOP, Inc.
409 A.2d 1262 (Court of Chancery of Delaware, 1979)
In Re Lukens Inc. Shareholders Litigation
757 A.2d 720 (Court of Chancery of Delaware, 1999)
Kaplan v. Centex Corporation
284 A.2d 119 (Court of Chancery of Delaware, 1971)
Emerald Partners v. Berlin
787 A.2d 85 (Supreme Court of Delaware, 2001)

Cite This Page — Counsel Stack

Bluebook (online)
In re Cornerstone Therapeutics Inc. Stockholder Litigation, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-cornerstone-therapeutics-inc-stockholder-lit-delch-2014.